Inovio Pharmaceuticals (NASDAQ:INO) Stock Keeps “Overweight” Rating at Piper Sandler

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “overweight” rating restated by equities researchers at Piper Sandler in a report issued on Wednesday, Benzinga reports. They presently have a $6.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $8.00. Piper Sandler‘s price objective would indicate a potential upside of 349.10% from the stock’s previous close.

INO has been the topic of several other research reports. Zacks Research lowered Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 12th. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Jefferies Financial Group restated a “buy” rating and set a $8.00 price objective (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, HC Wainwright set a $5.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, November 2nd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.33.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.34 on Wednesday. Inovio Pharmaceuticals has a one year low of $0.56 and a one year high of $2.72. The company has a market cap of $147.20 million, a price-to-earnings ratio of -1.53 and a beta of 1.71. The business’s 50 day moving average price is $1.18 and its 200 day moving average price is $1.27.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $2.27 million. On average, analysts predict that Inovio Pharmaceuticals will post -0.74 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC raised its holdings in Inovio Pharmaceuticals by 46.5% in the 2nd quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,554 shares during the period. HighTower Advisors LLC increased its position in shares of Inovio Pharmaceuticals by 104.8% during the third quarter. HighTower Advisors LLC now owns 26,076 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 13,346 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $33,000. Engineers Gate Manager LP acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $37,000. Finally, Green Alpha Advisors LLC raised its stake in shares of Inovio Pharmaceuticals by 68.8% in the 3rd quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 46,802 shares during the period. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: VOCERYQ was approved to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Inovio expects the treatment to be available for ordering and shipment about 60 days after approval, with a full commercial launch in the first quarter of 2027. The company says the approval validates its DNA-medicine platform. INOVIO Q3 2026 results and business highlights
• Positive Sentiment: Inovio reported $80.5 million in net proceeds from a recently completed public offering to support VOCERYQ’s launch. It also outlined a cash runway into late Q4 2027 and is targeting a European filing by year-end 2026, which could help support commercialization plans. Inovio cash runway and launch plans
• Neutral Sentiment: The company will participate in the Jefferies Global Healthcare Conference on November 18. The event may provide investor visibility, but no new business developments were announced with the notice. Upcoming investor conferences
• Negative Sentiment: Third-quarter results missed analyst expectations: Inovio reported a loss of $0.50 per share versus the $0.21 loss consensus, while revenue was $0.30 million compared with estimates of $2.27 million. The shortfall could weigh on sentiment even as investors focus on VOCERYQ’s launch prospects. Q3 earnings results

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.